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Abstract  
 
Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) is a key inhibitory regulator of T-cell function. 
Its expression is predominantly intracellular however, many theories surrounding it’s 
inhibitory action do not account for its endocytic behaviour. Recent reports have suggested a 
process of trans-endocytosis through which CTLA-4 internalises the ligand (CD80/CD86) 
from antigen presenting cells and prevents ligand binding to its stimulatory homologue CD28. 
The endocytic pathway of CTLA-4 is currently ill-defined and has a central role in this novel 
theory. Previous evidence suggests CTLA-4 is internalised via clathrin-dependent endocytosis 
(CDE). However observations in a transfected CHO cell model have suggested internalisation 
independent of this pathway. In this study CTLA-4 showed the same endocytic recycling 
behaviour when transfected into a HeLa cell line. Immunostaining showed a strong degree of 
co-localisation between internalising CTLA-4 and the transferrin receptor (which is 
classically associated with CDE). Co-localisation with Adaptor-Protein 1 suggested 
exocytosis from the trans-Golgi network to the plasma membrane was also clathrin-
dependent, however, no association was observed with clathrin directly. Little CTLA-4 co-
localisation to a lysosomal marker suggests that only a small proportion of the cytosolic 
receptor is targeted for degradation.  CDE was inhibited by transfection of shRNA for 
Adaptor Protein 2 (AP-2). In CTLA-4
+
 CHO cells knock down of AP-2 resulted in decreased 
intracellular CTLA-4 but this was not statistically significant. This data supports but does not 
confirm that CTLA-4 can internalise independent of CDE.
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1.0 Introduction 
1.1 Functional characteristics of Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) 
Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) is an inhibitory receptor expressed in both 
activated T-cells [1, 2] and T-regulatory cells (Treg) [3, 4]. T-cells are activated by T-cell 
receptor ligation to antigenic peptide bound to Major Histocompatibility Complex (MHC) 
which is expressed by antigen presenting cells (APC). Additional co-stimulation by associated 
receptors such as CD28 (which binds CD80/CD86 on APC) is also required to potentiate a 
full response [5].  Conversely, inhibitory receptors prevent excessive or self-reactivity and are 
required to maintain immune homeostasis (reviewed in [6, 7]). CTLA-4 is the structural 
homologue of CD28 and paradoxically shares the same ligands, yet has an antagonistic effect 
upon binding [8]. Its critical role is exemplified in CTLA-4
-/- 
deficient mice which develop 
fatal neonatal lymphoproliferative disease characterised by chronic lymphocytic infiltration 
into multiple organ systems [9, 10]. In addition, genetic polymorphisms in the CTLA-4 gene 
are associated with autoimmune diseases such as diabetes mellitus [11, 12] and rheumatoid 
arthritis [13] [14], thus demonstrating its role in maintaining self-tolerance and promoting 
clonal anergy [15]. 
The mechanisms through which CTLA-4 elicits its inhibitory functions are yet to be 
elucidated and many theories as to its mechanism of action are proposed (some notable 
concepts are listed in Table 1.1). However, many of these do not consider the unusual 
endocytic behaviour of the receptor or account for its existence. In contrast to CD28 which is 
expressed readily at the plasma membrane the surface expression of CTLA-4 is limited and 
the receptor is predominantly located within endosomal compartments [16]. This contradicts 
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the long-standing theory that CTLA-4 and CD28 simply compete for their common ligands 
and other such theories that assume significant receptor surface expression. 
Cell intrinsic (intracellular signalling) Cell extrinsic 
Inhibition of IL-2 expression via reduced 
NF-AT activity (reduced proliferation) 
[17]   
Direct competition with CD28 for their 
common ligands [18] 
Reduction in inflammatory transcription 
factor activity (NF-κB) [17] 
Induction of IDO by APC (reduced T-cell 
proliferation through tryptophan 
metabolite depletion) [19] 
Treg modulation: enhanced expression of 
the regulatory transcription factor 
FOXP3 and the anti-proliferative factor 
TGF-β [20, 21] 
inhibition of immune synapse formation 
through disruption of lipid raft [22, 23] 
Increased threshold for TCR activation 
[24]  
 
Table 1.1 Reported evidence for the inhibitory mechanism of CTLA-4 function. APC; 
Antigen Presenting Cell,CD28; Cluster of Differentiation 28, FOXP3; Forkhead box P3, IDO; 
Indoleamine 2,3-Dioxygenase, IL-2; Interleukin 2, NF-AT; Nuclear Factor of Activated T-
cells, NF-κB; Nuclear Factor-κB, TCR; T-cell receptor, TGF-β; Transforming growth factor 
β. (Table adapted from [25]). 
 
With regards to cell-intrinsic mechanisms, despite numerous reports there is no definitive 
association of CTLA-4 with inhibitory signalling pathways. This is consistent with the 
structure of the receptor, which has a short cytoplasmic domain with no immunoreceptor 
tyrosine-based activation motif (ITAM) [26]; classically associated with immune receptor 
signalling pathways. Given that 1) small changes in CTLA-4 surface expression have 
profound effects on T-cell activity [25], 2) Increases in surface expression are shown to be 
independent of CTLA-4 mRNA transcription [27], 3) There is differential surface expression 
of CTLA-4 in different T-cell subsets [28], it is highly likely that CTLA-4’s endocytic 
behaviour has a central role in its functionality. Consistent with this a novel mechanism of 
action for CTLA-4 is reported accounting for such recycling characteristics. CTLA-4 was 
shown to ‘rip’ CD80/CD86 from neighbouring cells and internalise it; thus depleting the 
ligand and making it unavailable for association with CD28 [29]. In light of this finding it is 
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important to further investigate the receptors internalisation and patterns of endosomal 
trafficking. 
1.2 Internalisation of surface CTLA-4 is attributed to the clathrin-dependent endocytic 
pathway. 
 Numerous publications suggest that CTLA-4 surface expression is restricted through rapid 
clathrin-mediated endocytosis (CDE) [30-32]; the most classically well-defined endoytic 
pathway. Clathrin is a structural triskelion protein involved in the coating and rounding of 
invaginating endosomes at the plasma membrane and other organelles [33]. The basic 
internalisation process mediated by clathrin is shown in Figure 1.1 and requires recruitment 
by adaptor protein-2 complex (AP-2) and action of accessory proteins [34].  
 
 
 
 
 
 
 
Figure 1.1 Schematic representation of clathrin-mediated endosome formation.  Clathrin 
is recruited to receptor microdomains by Adapter Protein-2. This binds a YVKM amino acid 
motif in the cytoplasmic domain of the receptor; thus linking clathrin to receptor (and bound 
ligand). Clathrin forms a structural coat which stabilises the membrane invagination. 
Accessory proteins such as epsins and endophilin facilitate bending and curvature of the 
membrane to form a clathrin-coated pit. Accessory proteins such as dynamin and 
amphiphysins are required for membrane cleavage and the pit is pinched off to form a coated 
vesicle. Upon internalisation the early endosome is uncoated and the components recycled 
back to the plasma membrane. 
 
 
 
 
 
 
 
 
  
  
Clathrin 
AP-2 
Accessory proteins 
Receptor 
Ligand 
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AP-2 recruitment is the first stage of vesicle formation forming the link between 
transmembrane receptors and clathrin. The cytoplasmic tail of CTLA-4 contains a variant of a 
conserved tyrosine-based amino acid motif which binds the µ-subunit of the AP-2 (Tyrosine-
Valine-Lysine-Methionine) [27, 31, 35]. It is previously observed that this interaction 
facilitates CTLA-4 internalisation, whereas alternative amino acids around this motif in the 
cytoplasmic tail of CD-28 are restrictive [36]. Additionally TCR activation is shown to 
upregulate phosphorylation of Tyr
201
 via src kinases which prevents binding of AP-2 and 
permits binding of phosphatidylinositol-3-kinase and SHP-2 kinases (kinases associated with 
signal transduction). Potentially this promotes both the surface retention and activity of 
CTLA-4, which suggests through AP-2 CDE is involved in the balance of surface activity 
versus internalisation [35, 37] [38-40].  
 Chimeric protein studies have showed increased internalisation of CD28 when engineered to 
express the cytoplasmic domain of CTLA-4 and increased surface retention of a CTLA-4 
construct expressing the cytoplasmic domain of CD28 [16]. However intracellular CTLA-4 is 
still observed when mutated at Tyr
201
 which suggests it can be internalised in an alternative 
fashion independent of clathrin [41, 42]. In support of this evidence has shown 1) CTLA-4 
may internalise through a non-clathrin-coated mechanism involving the reorganisation of F-
actin microfilaments. 2) Mutant CTLA-4 expressing the transmembrane and cytoplasmic 
domain of CD28 can still trans-endocytose ligand, suggesting only the extra-cellular domain 
is necessary for its function (both unpublished data). This is consistent with studies in CTLA-
4
-/- 
mice where re-introduction of CTLA-4 lacking the cytoplasmic domain promotes the 
restoration of a wild type phenotype [43].  
As this body of evidence suggests CDE is not necessary for CTLA-4 function the significance 
of the CDE route requires clarification and alternative or redundant endocytic pathways must 
be characterised.    
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1.3 Overview of CDE in intracellular trafficking and regulation of CTLA-4 expression 
Once internalised the fate of CTLA-4 and the proportions of receptor targeted for different 
cellular compartments are not completely defined (potential trafficking pathways are shown 
schematically in Figure 1.2).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Potential endocytic trafficking pathways of CTLA-4. Once internalisation 
clathrin-coated vesicles uncoat and fuse to form early endosomes. From here CTLA-4 may be 
recycled back to the surface directly or via sorting endosomes. Alternatively early endosomes 
may mature to form Multi-Vesicular Bodies (MVB). From here CTLA-4 may be recycled via 
the trans-Golgi network (TGN) where protein sorting occurs. Clathrin-coated vesicle 
formation at the surface requires AP-2 whereas transport from the TGN requires AP-1 
(reviewed in [34]). The TGN may regulate overall receptor expression through trafficking to 
lysosomes via MVB [44] . Within lysosomes CTLA-4 may be degraded or recycled through 
active secretion (Image adapted from [45]).  
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CDE has been most extensively defined by studies of the transferrin receptor (CD71); an 
archetypal CDE recycling receptor involved in the cellular uptake of Fe
2+
 and Fe
3+
-bound 
transferrin (reviewed in [45]) . When considering classical CDE in context of CTLA-4 trans-
endocytosis the documented similarities and differences between CD71 behaviour must be 
considered.  For CD71 iron molecules (cargo) dissociate in the acidic environment of the 
early endosome. Following geometry-based sorting processes (through an increased 
stoichiometric surface:volume ratio of narrowing microtubules in the recycling endosomes) 
over 99% of CD71 is recycled back to the cell surface [46]. Similar to CD71 it is plausible to 
consider that it CTLA-4 separates from cargo (trans-endocytosed ligand) and is recycled as 
this is energetically favourable. However in contrast it’s ligand would be targeted for 
lysosomal degradation whereas Fe
2+/3+
 would traffic to where required. Supporting this 
reported work using the lysosomal inhibitor bafilomycin A results in increased internalised 
CD80/CD86 but no concurrent increase in CTLA-4 [29]. This suggests the ligand is targeted 
for lysosomal degradation whereas the receptor is diverted along the pathway. However, this 
is not consistent with other studies that have identified both the presence of CTLA-4 and its 
active secretion from the lysosomal compartment [41] . Another observation which suggests 
the trafficking of CTLA-4 is more complex than CD71 is that the receptor is shown to 
accumulate in the perinuclear area close to the microtubule organising centres and be resistant 
to degradation [47, 48]. It also accumulates in late endosomes (multi-vesicular bodies), and as 
a specific signals (for example ubiquitination [49, 50]) are required for sorting into these 
mature compartments it may suggest CTLA-4 trafficking is subject to additional regulatory 
steps not associated with classical CDE.   
CDE is associated with both endocytic and exocytic events and although largely beyond the 
scope of this investigation it is important to note this exocytic pathway in context of the 
regulation of CTLA-4 surface expression. AP-1 binds the same cytoplasmic motif as AP-2 but 
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is associated with the trans-Golgi network; where newly synthesised proteins are sorted into 
different cellular compartments [51]. From here the receptor may be trafficked to the cell 
surface via recycling endosomes or be targeted to lysosomes via MVB depending signals as 
yet to be elucidated. 
1.4 Experimental aims 
Previously the transfection of CTLA-4 into a Chinese Hamster Ovary (CHO) cell line has 
been used to characterise the endocytic behaviour of CTLA-4 in vitro. In light of the 
implications of trans-endocytosis on CTLA-4 functionality, it is important to more precisely 
investigate its endosomal behaviour and challenge whether pathways are specifically clathrin-
dependent. Association of CTLA-4 to CDE will be analysed through observing co-
localisation of the receptor with known CDE-associated cellular markers. This will require the 
progression of the CHO cell model into a human cell line as such markers are not available 
for the hamster species. Transfection into a human HeLa cell line will also be a step 
progression towards a more physiological system. It will then also be examined whether 
CTLA-4 can internalise via pathways independent of clathrin. shRNA (small hairpin RNA) is 
a useful technique for silencing genes of specific of interest and this will be used to 
specifically knock down AP-2, thus preventing the formation of clathrin-coated pits and 
blocking CDE.  
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2.0 Materials and Methods 
2.1.1 Culture media, solutions and reagents 
Mammalian Cell 
Culture  
Complete DMEM Dulbecco's Modified Eagle Medium (DMEM) [Invitrogen, 
UK], 10% Fetal Bovine Serum  (FBS) [BioSera, Sussex, UK], 
1% Penicillin and 1% Streptomycin [both Invitrogen] 
 
G418 Gentamycin 50µg/ml [Invitrogen] 
 
PBS Phosphate Buffered Saline (8g/l NaCl, 0.26/l KCl, 1.15g/l 
NA2HPO4, 0.2g/ml KH2PO4); 1 PBS tablet added per 100ml 
distilled H20 [Oxoid, Basinstoke,UK]    
 
Trypsin Trypsin 0.05% EDTA [Invitrogen] 
 
 
Bacterial Cell Culture 
 
Circle Grow 0.04 w/v in dH2O [MP biosciences, Cambridge, UK] 
 
Select Agar 0.015 w/v in circle grow [Sigma, UK] 
 
SOC Medium Super Optimal Broth, [New England Biolabs, Herts, UK]  
 
Chloramphenicol 30µg/ml supplemented in agar plates 
   
Additional Reagents 
 
Lipofectamine Lipofectamine 2000 transfection system [Invitrogen] 
 
Mounting Medium Vectashield mounting medium with DAPA [Vector 
Laboratories, Peterborough, UK] 
 
PFA 3% PFA in PBS [Sigma, UK] 
 
Saponin 0.1% in PBS [Acros Organics] 
 
Plasmid purification kit QIAprep spin miniprep kit [QIAGEN, Sussex, UK] 
 
Electoporation Solution  AMAXA nucleofector kit T [Lonza International] 
Cholera Toxin   Red Fluorescent Protein labelled Cholera Toxin (RFP) 
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2.1.2 Fluorescence Staining Reagents 
  Target Antibody Species Dilution Company 
Primary 
CTLA-4 
ticilimumab Human 1/10000 Pfizer 
C19 Goat 1/250 Santa Cruz 
11G1 Mouse 1/100 - 
Clathrin ab6316-200 Goat 1/500 Abcam 
γ-adaptin ab21980 Mouse 1/250 Abcam 
Secondary 
α-human 
IgG 
Alexa Fluor-488 Mouse   1/500 Invitrogen 
 α-mouse 
IgG 
Alexa Fluor-488 Donkey 1/500 Invitrogen 
 α-goat IgG Alexa Fluor-647 Donkey 1/500 Invitrogen 
Direct 
Conjugates 
CTLA-4 
CTLA-4 PE Mouse 1/500 
BD 
Biosciences 
CTLA-4 APC Mouse 1/500 
BD 
Biosciences 
Tranferrin 
Receptor 
Transferrin-647  Human 1/100 Invitrogen 
Lysosome  LAMP1-Cy5 
Rabbit α-
human 
1/250 Abcam 
      Table 2.1. Antibodies and fluorecently-labelled conjugates used for immunostaining 
in confocal and flow cytometry experiments.  
 
 
2.2 Cell Culture and transfection of CTLA-4 into a HeLa cell line 
HeLa cells were cultured in complete DMEM medium at 37ºC, 5% CO2. Upon reaching 90-
95% confluency, cells were washed with PBS, split using 0.05% trypsin EDTA and 
replenishing the DMEM culture medium. A pre-established Chinese Hamster Ovary (CHO) 
cell line expressing human CTLA-4 in a pCDNA3.1 expression vector was cultured in the 
same manner. To induce CTLA-4 expression in HeLa cells this construct was transfected 
using Lipofectamine 2000 Transfection Reagent [Invitrogen] according to the manufactures 
guidelines.  
To identify the optimum ratio of DNA to Lipofectamine reagent an enhanced green 
fluorescent protein (pmaxGFP) control plasmid construct [AMAXA] was transiently 
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transfected into HeLa cells cultured on glass coverslips in a 24-well plate. 1-3µg DNA and 1-
3µl Lipofectamine were transfected and cells cultured for up to 48h. DNA and Lipofectamine 
were diluted in 50µl of opti-MEM (Invitrogen) and incubated for 5min. These were then 
combined for 20min, 100µl added per 0.5x10
6 
cells and incubated at 37ºC 5% CO2 for 4h. The 
solution of DNA/Lipofectamine complexes was then aspirated and replaced with 500µl of 
DMEM medium.  
To establish a stable cell line the transfection was performed in 25cm
2
 flasks and the reagents 
scaled up accordingly. Transfected cultures were then treated with 500µg/ml G418 in DMEM 
culture medium for 7 days. Positive clones were also selected using a BD FACSAria cell 
sorter. Flow cytometry was performed pre- and post-cell sort to determine CTLA-4 
expression levels. 
2.3.1 CTLA-4 internalisation assay 
CTLA-4
+
 HeLa or CHO cell cultures were trypsinized and resuspended at ~ 1x10
6 
cells/ml. 
500µl of cell suspension was then cultured on poly-L-lysine coated coverslips for 16h. Cells 
were washed with PBS and incubated with a primary α-CTLA-4 antibody for 30min. Surface 
staining was performed at 4ºC, whereas the recycling pool was stained at 37ºC. Cells were 
then washed with PBS and fixed for 15min in 3% PFA. Cells were washed with PBS and 
permeabilised with 0.1% saponin.  An appropriate secondary fluorescently-conjugated 
antibody diluted in 0.1% saponin was used to stain the pool of internalised receptor (Table 1). 
Cells were then washed with PBS and the coverslips allowed to air dry. Coverslips were 
mounted on glass slides with mounting medium containing the nuclear stain DAPI and sealed 
with varnish. An alternative version of this procedure was performed in some HeLa cell 
experiments, where surface and intracellular CTLA-4 was stained simultaneously. Here cells 
were labelled with primary α-CTLA-4 antibody for 30min 37ºC. They were then washed three 
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times in ice cold DMEM and surface receptor stained with Alexa Fluor-488 conjugated 
antibody. Cells were then fixed and permeabilised as described above and CTLA-4 
internalised from the cell surface stained with an Alexa Fluor-555 secondary conjugate. 
Recycling CTLA-4
+
 HeLa cells was also co-stained with the transferrin receptor (CD71) at 
37ºC to identify commonality between their internalisation pathways. CD71 internalisation 
was tracked using fluorescently tagged transferrin which is internalised bound to the receptor 
upon ligand binding. For this experiment cells were serum starved for 15min prior to staining 
to prevent competitive binding with the transferrin within FCS.  
2.3.2 Co-localisation of CTLA-4 with endosomal markers 
To co-stain for CTLA-4 with endosomal markers CTLA-4
+
 HeLa cells were fixed and 
permeablised prior staining to allow access of primary antibodies to the different intracellular 
compartments. Both a cells surface and intracellular CTLA-4 expression was therefore 
identified in these experiments. Cells were stained for clathrin to identify direct CTLA-4 co-
association with clathrin-mediated pathways. They were also stained for the γ-adaptin subunit 
of AP-1 to identify clathrin-mediated transport from the TGN to the plasma membrane. Cy-5 
conjugated Lysosomal-Associated Protein-1 (LAMP-1) was used as a marker for lysosomes 
in conjunction with both clathin and γ-adaptin. 
 2.4.1 Cloning of shRNA plasmid constructs 
Plasmid constructs encoding shRNA for the µ-subunit of AP-2 (AP2M1 gene) and two 
control constructs were obtained from Origene (Fig 4). 2µl of reconstituted DNA was added 
to 80µl of chemically competent DH5-α e.coli on ice for 30min. Bacteria were then heat 
shocked at 42ᵒC for 45sec and transferred back to ice immediately. 250µl of SOC medium 
was added and cultures transferred to a rotary shaker for 1h. 
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             B)                      
 
 
 
 
 
 
Fig 2.1 HuSH shRNA construct against AP2M1 in a pRFP-C-RS vector 
(OriGene). A) shRNA was ready-cloned into the vector to be expressed via a U6 
promotor. Vector contained chloramphenicol and puromycin resistance genes for 
selection of transfected clones. Red fluorescence protein (RFP) was expressed under a 
CMV promoter and used to visually identify transfected cells. B) The shRNA insert 
sequence for two controls and four AP2M1 shRNA constructs. 
 
 
 
 
 
 
Construct shRNA sequence Abbreviation 
TR30014 None C1  
TR30015 Scrambled C2 
FI1358997 TTCCACCAGTGTGTGCGACTCAGCAAGTT 97 
FI1358998 AGCAAGTTTGACTCTGAACGCAGCATCAG 98 
FI1358999 TGGTGATGAAGAGCTACCTGAGTGGCATG 99 
FI1359000 GATGTGCTGGAGAGTGTGAACCTGCTCAT 90 
A) 
B) 
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Bacteria were then grown overnight on 30µg/ml chloramphenicol agar plates at 37ºC, 5% 
CO2. Plasmid DNA was purified using a QIAprep spin miniprep kit according to the 
manufacturers’ specification [QIAGEN] and stored at -20ºC. The plasmid DNA concentration 
was quantified by a nanodrop spectrophotometer [Thermo Scientific, Wilmington, USA].  
 
2.4.2 Transient transfection of shRNA into CTLA-4
+ 
CHO and CTLA-4
+ 
 HeLa cell lines. 
Cells were trypsinized and resuspended at ~ 1x10
6 
cells/ml. CTLA-4
+ 
CHO cells were 
transfected with 5µg of each shRNA plasmid using an Amaxa cell line nucleofector kit T. An 
Amaxa nucleofector electroporation device set to program U-023 was used for high efficacy 
transfection of the CHO cell line. To identify the most efficiently transfected construct cells 
were initially cultured overnight in 6-well plates, trypsinized, and flow cytometry performed 
to quantify expression. For imaging experiments 50µl of electroporated cells were added to 
coverslips in a 24-well plate and made up to 500µl with complete DMEM. Cells were 
incubated for 24h at 37ºC, 5% CO2 prior to staining. 
 CTLA-4
+ 
HeLa were transiently transfected on coverslips according to the transfection 
optimisation protocol described in section 2.2. Concentrations of DNA and lipofectamine 
were chosen consistent with the result of the assay optimisation. 
2.5 Flow cytometry 
All fluorescently stained samples were stored in the dark at -2 ºC  prior to flow cytometry 
experiments, which  were performed using either a FACSCalibur [Becton Dickinson] or a 
Dacko cyAnADP device and data collected by Cell Quest Pro v5.2.1 and Summit v4.3 softwear 
respectively. Data was analysed using FlowJo v8.5.3 or Summit v4.3.  
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2.6 Confocal microscopy 
Imaging was performed using either a Zeiss LSM 510 or a Zeiss LSM 780 inverted laser 
confocal microscope under the supervision of Dr Omar Qureshi. All images were collected 
under a X100 oil immersion objective lens. ImageJ [Wayne Rasband, NIH] software was used 
to process and analyse collected images. ImageJ was also used to calculate the mean 
fluorescence intensity of staining for different fluorochromes. This was an automated 
calculation following the selection of a desired area of image.  
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3.0 Results 
3.1 Characterisation of the endocytic nature of CTLA-4 in a transfected CHO cell line. 
We firstly aimed to demonstrate the endocytic recycling of Cytotoxic T-Lymphocyte Antigen-
4 (CTLA-4) using an established CTLA-4 a transfected Chinese Hamster Ovary (CHO) cell 
line. Staining for CTLA-4 at 4ºC could identify protein solely expressed at the plasma 
membrane as cells are metabolically inactive at this temperature and endocytic pathways are 
halted. At a physiological temperature (37ºC) the cells cellular transport is permitted, thus the 
recycling pool of CTLA-4 can be demonstrated. Flow cytometry data showed that at 4ºC 
surface stained CTLA-4 expression was ten-fold lower than at 37ºC. This suggests that 
CTLA-4 is expressed at the plasma membrane and that endocytic pool of CTLA-4 is directed 
to the cell surface where it able to bind fluorescently-conjugated antibody (Fig 3.1A). The 
staining intensity at 37ºC was very similar to that when the total CTLA-4 was stained 
indicating the majority of CTLA-4 within a cell is recycling. Additionally the fluorescence 
intensity of labelled CTLA-4 increases in a near linear fashion over time. This further 
suggests a continual endocytic turn-over of receptor trafficked to the plasma membrane, 
fluorescently labelled and then internalised (Fig 4B). To support this theory confocal 
microscopy was performed to visualise the cellular localisation of the recycling pool of 
CTLA-4. When CHO cells were stained with anti-CTLA-4 for at 37ºC images showed the 
receptor was predominantly located in discrete intracellular vesicles dispersed throughout the 
cytosol (Fig 3.2). There was little staining of the receptor at the cell surface indicating the 
majority is expressed within endosomes at physiological temperature. 
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Figure 3.1 Characterization of the surface and intracellular expression of CTLA-4 
 in CHO cells by flow cytometry.  A) CHO cells transfected with wild type CTLA-4 were 
incubated with anti-CTLA-4 antibody for 30min at 4ºC (surface pool) and 37ºC (recycling 
pool). The total pool was also stained by fixing and permeablising the cells prior to 
staining. B) Cells were incubated with anti-CTLA-4 antibody over a 1 hour time course at 
37 °C. Mean fluorescence intensity (MFI) of CTLA-4 positive cells increases with time. 
mouse IgG2a isotype was used as a negative control. n=1 for both experiments. 
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Figure 3.2 The cellular localisation of CTLA-4 in CHO cells. CHO cells 
expressing CTLA-4 were stained with anti-CTLA-4 antibody at 37ºC. Cells were then 
fixed, permeablised and stained with a FITC-conjugated secondary antibody (green). 
Mounting medium containing DAPI was used to stain cell nuclei (blue). Image shows  
the recycling pool of CTLA-4 in intracellular vesicular endosomes. Image 
representative of n=2 independent experiments. 
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3.2 Transfection of CTLA-4 into HeLa cells 
The association of CTLA-4 with clathrin-mediated endocytosis (CDE) could be identified 
using fluorescently-labelled antibodies to various endosomal markers of the pathway and 
analysing co-localisation. As these antibodies were not applicable for a CHO cell species the 
model was transferred to a human HeLa cell line. To optimise transfection using 
Lipofectamine reagent a CTLA-4-GFP construct was used to allow easy visualisation of 
successful transfectants via confocal microscopy. Varying the ratio of Lipofectamine to DNA 
indicated that the optimal ratio was 1:1 as the highest proportion of CTLA-4 positive cells 
with the brightest GFP signal was seen at this ratio (Fig 3.3). A greater proportion of 
Lipofectamine caused a greater degree of membrane disruption and blebbing (DNA:LF 1:2), 
along with increased cell death. A higher ratio of DNA did not improve transfection and 
efficacy was poor (DNA:LF 2:1). Transfections were also carried out over either one or two 
days, with a two day transfection assay giving optimal results (data not shown). However no 
numerical data for this evidence was produced and findings were based on microscope 
visualisation at the time of investigation. 
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Figure 3.3 Confocal microsopy images representing the optimization of CTLA-4 
transfection into HeLa.  Expression of CTLA-4 GFP by HeLa cells was induced by 
transfection of a plasmid construct via the lipofectamine 2000 (LF) transfection 
system (Invitrogen). Optimisation of the protocol was achieved by varying the 
DNA/lipofectamine ratio. Two representative images for each ratio is shown. 
Mounting medium containing DAPI (blue) was used to stain cell nuclei.  
  
DNA:LF 
1:1 
1:2 
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Flow cytometry was performed on the newly transfected cell line to confirm and characterise 
CTLA-4 expression (Fig 3.4B). Staining for the surface and recycling pool of CTLA-4 
revealed a trend consistent with that seen in CHO cells (Fig 3.1), with the majority of CTLA-
4 within a cell recycling and labelled at the cell surface at the physiological temperature. 
There was also a ten-fold difference seen between this pool and the surface pool at 4ºC. 
However, despite successful transfection, CTLA-4 expression was low with the majority of 
cells CTLA-4 
(low)
. The cell line also showed a high degree of cell death. Therefore the cells 
were sorted for CTLA-4 
(hi)
 expression, and flow cytometry confirmed >95% of cells now 
expressed high levels of the receptor (Fig 3.4A). 
In order to more accurately quantify the amount of surface versus intracellular expression of 
CTLA-4 the two pools were co-stained simultaneously using secondary antibodies conjugated 
to two different fluorochromes (Fig 3.5). This technique could later be used to quantify the 
knock down effect on clathrin-mediated endocytosis. Confocal images showed CTLA-4 
expression in HeLa cells had a similar distribution to the established CHO cell line, with a 
higher fluorescence intensity of the intracellular portion. The mean fluorescence intensity 
(MFI) showed the surface to intracellular ratio of CTLA-4 was approximately 1:3 in both 
HeLa and CHO cells, which added further evidence that CTLA-4 is predominantly 
intracellular in both cell lines.  
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 Figure 3.4 Characterisation of CTLA-4 expression in transfected 
HeLa cells by flow cytometry. A) Transfected HeLa were sorted by 
FACS for CTLA-4
(hi). 
B) HeLa cells transfected with wild type CTLA-4 
were incubated with anti-CTLA-4 antibody for 30min at 4ºC (surface 
pool) and 37ºC (recycling pool). The total pool was also stained by 
fixing and permeablising the cells prior to staining. 
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Figure 3.5 Double staining of surface and intracellular CTLA-4 in CHO and 
HeLa cells.  Cells were labeled with anti-human CTLA-4 primary antibody at 37ºC.  
Surface CTLA-4 was stained with Alexa Fluor 488-conjugated secondary (green). 
Cells were then fixed, permeablised and intracellular CTLA-4 stained with Alexa 
Fluor 647-conjugated antibody (red). Mounting medium containing DAPI was used 
to stain cell nuclei (blue). Graph shows the surface/intracellular ratio of CTLA-4  
using the mean fluorescence intensity of individual cells. The MFI was found to be 
0.34±0.025 and 0.366±0.288 for HeLa and CHO cells respectively (n=20). 
  
Surface 
Surface Intracellular Surface + Intracellular 
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3.3 Identification of the endocytic pathway of internalised CTLA-4 in HeLa cells. 
To investigate the fate of endocytosed CTLA-4 HeLa cells were surface stained with anti-
CTLA-4 antibody at 5min, 30min & 60min and the location of labeled receptor viewed at 
three time points (Fig 3.6). At 5min the intensity of CTLA-4 staining was greatest at the 
surface in some cells. However endocytic vesicles containing CTLA-4 could be observed at 
this time point indicating rapid and constitutive internalization of the receptor (Fig 3.6A). At 
30min vesicles containing CTLA-4 could be seen dispersed throughout the cytoplasm with 
less visible staining at the cell surface (Fig 3.6). At 60min there was an increased intensity of 
CTLA-4 staining around the perinuclear area, with an accumulation within centrally localized 
vesicles (Fig 3.6C). 
 
 
 
 
 
 
 
 
 
 
 
5min 30min 60min 
Figure 3.6. Cellular localisation of internalised CTLA-4 in HeLa cells. HeLa 
cells transfected with CTLA-4 were stained with -CTLA-4 antibody for a 5-60min 
duration. Following fixation and permeablisation cells were stained with a 
secondary 488-conjugated antibody (green). Images representative of n=1 
experiment. 
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To identify any geometry based association between CTLA-4 and clathrin-mediated 
endocytosis (CDE) transfected CTLA-4 was firstly co-stained with clathrin itself. A 
lysosomal marker LAMP-1 (lysosome-associated membrane protein-1) was also added to 
identify CTLA-4 and clathrin within this subcellular compartment (Fig 3.7). 
Co-staining identified little co-localisation when CTLA-4 with clathrin (Fig 3.7A). Clathrin 
staining was restricted to the plasma membrane (blue) whilst consistent with Fig 3.5 little 
CLTA-4 was stained at the cell surface and a strong signal shown within vesicular bodies 
(green). There appeared some degree of convergence between the lysosomal marker and 
CTLA-4 (as shown by yellow vesicles in Fig 3.7B, Fig 3.7C). Areas of co-localisation were 
identified towards the centre of the cell but more predominantly at the periphery. This 
suggests a small but notable proportion of intracellular CTLA-4 is targeted for lysosomal 
degradation, however, no clathrin was associated with this endosomal compartment. 
Cells were also co-stained for the transferrin receptor (CD71): an archetypal endocytic 
receptor known to internalise specifically in a clathrin-dependent manner (Fig 3.8). Surface 
staining of both receptors at physiological temperature would identify any commonality or 
convergence of their internalisation pathways, thus linking CTLA-4 to CDE. Confocal 
microscopy images identified a strong degree of co-localisation between CTLA-4 (green) and 
the CD71 (red) in some cells (yellow vesicles Fig 3.8). These were particularly prominent 
around the perinuclear area where the staining intensity was greatest, and support a link 
between CTLA-4 and CDE. However, singularly stained vesicles indicated there remains 
some disparity in the endosomal pathways of each receptor. It was noted that some cells 
appeared to express high levels of CTLA-4 did not stain well for CD71 and cells expressing 
little CTLA-4 seemed to have more internalised CD71 in some instances. This indicated a 
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preferential internalisation of either one of the receptors, and suggested their uptake may have 
influences on eachother. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.7 Co-staining of CTLA-4 and endocytic markers in CTLA-4 transfected 
HeLa cells.  CTLA-4 positive HeLa cells were fixed, permeabilised and stained with 
anti-CTLA-4 and anti-clathrin antibodies for 30min. A) CTLA-4 was labelled with a 
Alexa-Fluor-488 secondary antibody (green). Arrows show transfected cells. Clathrin 
was labelled with a Alexa Fluor-647 (blue). B) Cells were also co-stained for the 
lysosomal marker LAMP-1 with Cy5-conjugated  anti-LAMP-1 antibody (Red). C) 
Staining for CTLA-4 and both endosomal markers. Images representative of n=1 
experiment. 
A) CTLA-4 + Clathrin B) CTLA-4 + Lysosome 
C) CTLA-4 + Clathrin + 
Lysosome 
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To identify association of CTLA-4 with a clathrin-mediated intracellular sorting pathway it 
was also co-stained with γ-adaptin. This subunit of the Adaptor Protein-1 (AP-1) complex 
facilitates the formation of clathrin-coated vesicles budding from the trans-Golgi network 
(TGN) (Fig 3.9A). LAMP-1 was also stained to show whether CDE is involved in 
transporting CTLA-4 from the TGN to lysosomes directly (Fig. 3.9B, 3.9C). There was a 
small degree of co-localisation of CTLA-4 and γ-adaptin, particularly in areas of intense 
CTLA-4 staining towards the centre of the cell (sky blue vesicles Fig 3.9A), This may 
represent the newly synthesised pool of CTLA-4 or receptor transported to the TGN from 
different endosomal compartments for sorting. This is evidence that the transport of the 
 
CTLA-4 
Transferrin Receptor 
Co-localisation 
Figure 3.8 Co-Localisation of CTLA-4 and the transferrin receptor in HeLa cells. 
Hela cells expressing CTLA-4 were surface labelled with anti-CTLA-4 antibody and 
fluorescently labelled transferrin. Cells were fixed, permeabilised and stained for 
internalised receptor. Mounting medium was used to stain cell nuclei (blue). Confocal 
microscopy image (left) shows  vesicles containing internalised CTLA-4 (green) and 
transferrin (red). Right panel highlights a degree of co-localisation between CTLA-4 
and transferrin within intracellular vesicles (yellow) in the  enlarged area indicated left. 
Images representative of one independent experiment. 
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receptor from the TGN involves CDE. As demonstrated in Fig 3.7B, in this separate 
investigation a small proportion of CTLA-4 was identified as lysosomal by association with 
the lysosomal marker LAMP-1 (magenta vesicles Fig 3.9B). γ-adaptin was also shown to 
associate with lysosomes (orange vesicles Fig 3.9C) which suggested its involvement in 
receptor transport from the TGN to lysosomes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.9 Co-staining of CTLA-4 and endocytic markers in CTLA-4 transfected 
HeLa cells.  CTLA-4 positive HeLa cells were fixed, permeabilised and stained with 
anti-CTLA-4 and anti-γ-adaptin antibodies. Arrows highlight areas of co-localisation 
A) CTLA-4 was labelled with a Alexa-Fluor-350 secondary antibody (blue). γ-
adaptin  was labelled with Alexa Fluor-488 (green) B) CTLA-4 was also co-stained 
for the lysosomal marker LAMP-1 with Cy5-conjugated  anti-LAMP-1 antibody 
(Red).. C) Staining for CTLA-4 and both endosomal markers. Images representative 
of n=1 experiment. 
C) CTLA-4 + γ-adaptin 
+ lysosome B) CTLA-4 + lysosome 
A) CTLA-4 + γ-
adaptin 
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3.4 Pharmalogical blockade of clathrin-dependent endocytic pathways 
Examining whether CDE is essential for CTLA-4 internalisation required a CDE-specific 
blockade of this route without disruption of other modes of endocytosis. We therefore tested 
whether hypertonic blockade of endocytosis by sucrose solution was sufficient to achieve this 
specific CDE inhibition. CD71 internalisation is clathrin-dependent whereas cholera toxin 
hijacks multiple endocytic routes [52, 53], and both were seen within intracellular vesicles at 
30min without sucrose (Fig 3.10). Consistent with current literature, cholera toxin 
accumulated in the centre of the cell around the location of the Golgi apparatus [53]. Cells 
adopted a very elliptical morphology with a smooth membrane in the presence of sucrose and 
both internalisation of CD71 and cholera toxin was abrogated. Therefore sucrose disrupted 
both clathrin-dependent and independent pathways and was insufficient for the purposes of 
this investigation. 
 
 
 
 
 
 
 
 
 
29 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD71 Cholera Toxin Composite 
- sucrose 
+ sucrose 
Figure 3.10 Block of transferrin receptor and cholera toxin 
internalisation by sucrose. HeLa cells were incubated with Alexa Fluor-
647 conjugated α-CD71 antibody (blue) and RFP-conjugated cholera toxin 
(red) +/- the presence of 0.4M sucrose at 37ºc. Presence of sucrose 
abrogated the internalisation of both CD71 and cholera toxin. Image is 
representative of n=2 independent experiments. 
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3.5 shRNA knock down of the AP-2 µ-subunit in CTLA-4 CHO and HeLa cell lines. 
To produce more specific CDE inhibition expression of an essential component of clathrin-
coated pit formation was abrogated. This was achieved through transient transfection of an 
AP2 µ2-subunit shRNA plasmid construct with a red fluorescent protein (RFP) reporter. 
Firstly the procedure was optimised in CHO cells expressing CTLA-4. Four constructs 
(abbreviated to 97, 98, 99 and 90) against different segments of µ2 mRNA were available and 
flow cytometry was performed to see which construct was most highly expressed upon 
transfection (Fig 3.11). Transfection of all four constructs revealed RFP
+
 cells relative to 
untransfected, which confirmed successful shRNA transfection 
A control construct with scrambled shRNA insert was the most efficiently transfected (Fig 
3.11B), however of the AP-2 constructs the efficiency of 98 was the greatest, with both the 
highest percentage of CTLA-4+ shRNA+ cells (46.5%) and the highest RFP mean 
fluorescence intensity (Fig 3.11A and 3.11B). This construct was then taken forward for 
further knock down experiments. Interestingly the CTLA-4 MFI for shRNA positive cells 
also increased following transfection with all constructs. 
Following the conformation of successful shRNA transfection the effect of AP-2 knock down 
on CTLA-4 recycling was investigated in CHO and HeLa cells. CHO cells were transiently 
transfected with shRNA and receptor internalising from the cell surface labelled at 37ºC as 
previously described. Cells stained red (RFP
+
) could be identified as cells successfully 
transfected with shRNA (Fig 3.12A). In some CHO cells there appeared a reduced number 
vesicles containing CTLA-4 (green) in AP-2 knock down cells when compared to 
untransfected cells, and what receptor was labelled appeared to be restricted to the surface. 
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However, this was not true of all shRNA
+ 
cells. The mean fluorescence intensity of CTLA-4 
staining in these cells was calculated and found to be lower than that of both the positive  
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Figure 3.11. Transfection of shRNA constructs into CHO cells. Four RFP  
positive plasmid constructs containing shRNA inserts for  the  µ-subunit of 
AP-2  were transiently transfected into CTLA-4 positive CHO cells and 
incubated overnight. Constructs lacking the shRNA insert those containing 
scrambled shRNA were used as controls (C1 and C2 respectively). Following 
cell staining with anti-CTLA-4 antibody flow cytometry was performed to 
identify the most efficiently expressed shRNA construct. A) CHO cells 
singularly transfected with CTLA-4. B) Positive control (C1)  shows a 
population of  CTLA-4 positive RFP  positive  cells which confirms 
successful transient transfection. C) 98 was the most efficiently transfected 
construct, with the  highest percentage of RFP+  cells. D) Shows the mean 
fluorescence intensity (MFI) of CTLA-4 positive shRNA positive cells for 
each transfected construct (n=1). 
D. 
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controls and the untransfected cells (Fig 3.12B). This suggested the blockade of clathrin-
mediated endocytosis was inhibiting the CTLA-4 internalisation, however no statistical 
inferences could be drawn from this data due to lack of experimental replicates.  
HeLa cells were then transfected with shRNA and co-stained for both surface and intracellular 
CTLA-4 for more accurate quantification as previously described (Fig 3.5). Cells successfully 
transfected with shRNA via the previously optimised lipofectamine protocol were identified 
(red). However unlike in CHO cells the transfection did not visibly seem to decrease the 
proportion of intracellular CTLA-4 when compared to untransfected cells or control 
constructs (blue). In contrast an increased staining intensity was observed (blue panel Fig 
3.13). There was an observable increase in the intensity of CTLA-4 staining at the cell surface 
(green panel). However the RFP-signal from shRNA transfected cells was so intense it caused 
considerable cross-over into the Alexa fluor-488 emission spectrum causing a false positive 
CTLA-4 signal (Fig 3.13C). It was therefore impossible to accurately calculate the MFI of 
CTLA-4 and no quantitative data for the surface or intracellular CTLA-4 expression.   
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Figure 3.12 The cellular  localisation  of  CTLA-4 in transfected CHO cells 
following  shRNA knock down of the µ subunit of adapter protein 2 (AP-2). 
CTLA-4 positive CHO cells were transiently transfected with an shRNA-RFP 
construct to disrupt clathrin-mediated endocytosis. Cells were labelled with human 
CTLA-4 primary antibody at 37ºC. Fixed and permeablised cells were stained with 
Alexa fluor 488-conjugated anti-human to show internalised CLTA-4.  Mounting 
medium containing DAPI was used to stain cell nuclei (blue). A) Two confocal 
microscopy images showing CTLA-4 localisation (green) in cells transfected with 
AP-2 shRNA (magenta) and those shRNA negative (blue). B) The mean fluorescence 
intensity (MFI) of  CTLA-4  in shRNA  negative cells (UT),  those expressing two 
positive control constructs (C1 and C2) and shRNA  positive cells (98). Data 
representative of 5-11 cells in n=1 experiment. 
A) 
B) 
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Figure 3.13 Surface and intracellular  expression of CTLA-4 in transfected 
Hela cells following  shRNA knock down of the µ subunit of adapter protein 
2 (AP-2). Hela cells expressing CTLA-4 were transiently transfected with an 
shRNA-RFP construct to disrupt clathrin-mediated endocytosis. Cells were 
incubated with  anti-CLTA-4 antibody at 37ºC for 30min. Surface CTLA-4 was 
stained with Alexa Fluor 488-conjugated secondary antibody at 4 °C for 30min 
(green). Cells were fixed,permeablised and intracellular CTLA-4 stained with 
Alexa Fluor 647-conjugated antibody at 37 °c (blue). A) Confocal microscopy 
images showing CTLA-4 localisation in CTLA-4 positive AP-2 shRNA negative 
HeLa. B) CTLA-4 localisation of cells transfected with an shRNA-RFP control 
construct (arrow heads). C) CTLA-4 localisation in cells transfected with  AP-2 
shRNA-RFP  construct (arrow heads). Images representative of n=1 experiment.  
UT: Untransfected 
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4.0 Discussion 
Given recent observations suggesting the endosomal behaviour of Cytotoxic-T-Lymphocyte 
Antigen-4 (CTLA-4) has a fundamental role in its mechanism action, the objective of this 
investigation was to examine its endocytic behaviour. Determining whether or not CTLA-4 
internalisation was clathrin-dependent (CDE) was central to the study, due to conflicting 
reports as to its endosomal pathway (reviewed in [25]. 
Initially, previous observations of the receptors endocytic behaviour in a transfected CHO cell 
line were successfully replicated. Flow cytometry showed the surface expression (at 4ºC) of 
the receptor was limited but when staining at physiological temperature cytoplasmic CTLA-4 
was trafficked to the plasma membrane where it bound conjugated antibody. The fluorescence 
intensity increased over time and the fact there is finite space at the cell surface leads to the 
conclusion labelled receptor is internalised and represented a recycling pool of receptor (Fig 
3.1). This was confirmed by confocal microscopy images which showed intracellular vesicles 
containing CTLA-4 labelled at the cell surface (Fig 3.2). Notable in flow cytometry 
experiments was when the total expressed receptor was stained it was very similar to the 
recycling pool. This suggests that the majority of CTLA-4 is recycling, however the surface 
staining was performed live and total stains performed fixed. Therefore it is possible that the 
chemical stress of the fixing and permeabilisation process negatively affected the staining 
procedure and leads to an under-representation of receptor.  
To associate the trafficking pathway of CTLA-4 with CDE this model was transferred into a 
human (HeLa) cell line, so endosomal markers of the CDE pathway could be obtained. HeLa 
cells were transfected using lipofectamine reagent. Optimisation showed that the optimum 
ratio of DNA to lipofectamine was 1:1 (1.5µg:1.5µl) cultured for 2 days leading to a transient 
process. However, further refinement and more quantitative analysis would have been 
beneficial as the cationic reagent was still considerably cytotoxic causing morphology 
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changes and considerable cell death in culture. This was demonstrated when it was used at 
higher concentrations in the optimisation process (Fig 3.3). Once transfected the CTLA-4 
HeLa cells were initially unstable and the expression of the receptor was low. However, once 
sorted for CTLA-4(hi) a stable line with a high percentage expression was established (Fig 
3.4A). CTLA-4 expression in HeLa showed very similar recycling patterns as seen in CHO 
cells, confirming consistency between the two models. This consistency was demonstrated by 
the similar CTLA-4 staining intensities of the surface and recycling pool of CTLA-4 by flow 
cytometry (Fig 3.4B) and confocal microscopy images where the ratio of surface to 
intracellular CTLA-4 expression was comparable (Fig 3.5).  
Staining for the recycling pool over 60min in HeLa was analysed by confocal microscopy and 
it may have been favourable to support this with flow cytometry data as performed in CHO 
cells. However, images showed an accumulation of surface stained receptor in the perinuclear 
area at the hour time point (Fig 3.6) which is consistent with published reports that the 
receptor accumulates here around the microtubule organising centre and is resistant to 
degradation [41, 47, 54] . What was not possible to determine from this experiment is whether 
or not internalised CTLA-4 recycles back to the cell surface directly and in what proportion. 
This could be achieved by surface staining with anti-CTLA-4 fluorescently-conjugated 
antibody and surface staining again with an anti-antibody with a different fluorophore at set 
time points. By comparing the mean fluorescence intensities of the labelled and double-
labelled CTLA-4 the proportion of receptor that had recycled at least once could be 
established. 
In contrast to CHO cells transfection of CTLA-4 into HeLa allowed for its internalisation to 
be compared with transferrin receptor (CD71): classically associated with the clathrin-
dependent endocytic route. The fact there was a strong degree of co-localisation between 
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CTLA-4 and CD71 in some intracellular vesicles is evidence of a commonality between their 
endocytic pathways (Fig 3.8). This is suggestive that the endocytic pathway of CTLA-4 is 
clathrin-mediated. However, the fact there was also significant expression of each receptor in 
separate intracellular compartments may suggest their pathways merge or converge at 
different points. It may be informative to repeat the experiment on live cells and record the 
location of each receptor over a given time. What was also noted is that some cells which 
strongly expressed internalised CTLA-4 did not appear to show much internalised transferrin 
and visa versa (Fig 3.8). This could possibly suggest that the artificially high expression of 
CTLA-4 in HeLa results in competition between the receptor and CD71 for clathrin, 
membrane and associated machinery at the cell surface. This competition could further 
suggest CTLA-4 and CD71 share a common CDE internalisation pathway. Despite this the 
observation was not supported by a decrease in CD71 uptake in CTLA-4 HeLa compared to 
untransfected HeLa in flow cytometry experiments. However, a decrease in CD71 uptake was 
observed in experiments comparing a CTLA-4
+
 Jurkat T cell line and untransfected Jurkat 
cells.   
Despite the evidence supporting a common pathway between the two receptors it must be 
considered that CD71 internalisation requires direct ligand binding, whereas in contrast 
CTLA-4 is constitutively recycles and transiently upregulates in response to T-cell receptor 
(TCR) ligation in activated T-cell [55, 56]. More appropriate analogies between CTLA-4 and 
the glucose uptake transporter (GLUT4) receptor have been drawn [57]. GLUT4 is actively 
mobilised and recycles to the membrane in response to insulin binding to the insulin receptor 
[58], in the way CTLA-4 mobilises through TCR activity. In addition to CD71 it may 
therefore be interesting to compare CTLA-4 to receptors whose response is indirectly 
dependent on the activity of another plasma membrane receptor.   
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  When CTLA-4 was co-stained with clathrin to directly identify an association with CDE no 
apparent co-localisation was observed (Fig 3.7). This was surprising given published evidence 
of a positive association with clathrin coated-pit forming machinery [26, 30-32]  and this data 
showing co-localisation of the receptor with CD71. It was also surprising that clathrin staining 
was restricted to the plasma membrane despite cell permeablisation given its involvement in 
vesicular budding from the Golgi apparatus. Further investigation is required before the cause 
of this pattern of expression and lack of geographical connection can be ascertained. 
AP-1 is the adapter protein which associates CTLA-4 to clathrin and is essential for the 
clathrin-dependent endosomal transport originating from the trans-Golgi network (TGN) [34]. 
When vesicles containing CTLA-4 pinch off from the TGN it has been shown they can be 
either exported to the cell surface or traffic to mature endosomal compartments. In this way 
CDE may have an important role in regulation of surface and overall expression. To link 
CTLA-4 to CDE in transport from the TGN pathway the γ-subunit of AP-1 was fluorescently 
labelled in transfected HeLa (3.9). A notable degree of co-localisation was found towards the 
centre of cells. This is consistent with expected subcellular location of the Golgi apparatus i.e. 
adjacent to the nucleus, and supports previous work showing CLTA-4 association with AP-1 
[27, 59]. To confirm this it would be beneficial to additionally label a marker for the exocytic 
pathway from the TGN (for example the TGN marker syntaxin) to further confirm CTLA-4 
associated with AP-1. 
 
The quantity or origin of CTLA-4 targeted to lysosomes is not completely defined. In light of 
recent reports from the lab which have suggested CTLA-4 rips its ligand from antigen 
presenting cells (APC) through transendocytosis, it is important to further investigate whether 
internalised receptor bound ligand is targeted to lysosomes for degradation. In this study some 
CTLA-4 was found geographically co-localised to lysosomes (as shown by yellow vesicles in 
39 
 
Fig 3.7 and magenta vesicles in Fig 3.9). As CTLA-4 was stained intracellularly and not at the 
surface the source of lysosomal receptor was not established and given that lysosomes are the 
primary site of degradation, some lysosomal receptor may be as expected. However, the 
receptors co-localisation with lysosomes does not necessarily correlate to its breakdown. For 
example published data has suggested CTLA-4 can by-pass degradation through active 
secretion from lysosomes [27]. It would therefore be informative to visualise whether CTLA-
4 stained at the cell surface and trafficked to lysosomes could recycle to other endosomal 
compartments or back to the plasma membrane.  
 
Once an association between CTLA-4 and CDE had been established through endosomal 
markers the aim was to attenuate the CDE pathway and examine whether this abolished 
CTLA-4 internalisation. In this way an alternative internalisation independent of clathrin 
could be identified. Historically hypertonic sucrose solution has been used to block of this 
pathway (reviewed by Andrei I. 2008). Studies suggest this is through disruption of clathrin 
assemblage is shown by a reduced number of clathrin coated pits [60]. In line with this theory 
sucrose did abrogate the internalisation of CD71 in HeLa cells suggesting clathrin-dependent 
machinery was inhibited (Fig 3.10). However changes in cell morphology suggested other 
effects consistent with osmotic changes and inhibition of any membrane invagination. 
Cholera toxin binds to GM1 gangliosides which are lipid receptors associated with lipid rafts 
[52]. These lipid rafts are then internalised via clathrin-coated pits, caveolae (non-coated) or 
clathin/caveolin-independent mechanisms. As cholera toxin internalisation was also inhibited 
by sucrose and in keeping with previous findings it is suggested hypertonic blockade inhibits 
all major endocytic pathways (Fig 3.10). It was therefore insufficient for our purpose of 
targeting clathrin-dependent routes specifically. Intriguingly a proposed mechanism of action 
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of CTLA-4 is through disruption of lipid raft formation through association with GM1 and it 
is not implausible to also consider its role in endocytic regulation [61].   
shRNA is a useful tool for blocking specific elements of a pathway of interest, and this was 
used to block the formation of clathrin-coated pits through knock down of the AP-2 complex. 
In CTLA4
+
 CHO cells transfection of shRNA resulted in a decrease in intracellular CTLA-4 
when compared to controls, indicating that internalisation of surface receptor was repressed 
(Fig 3.12). This finding would suggest that the receptors major endocytic route is clathrin-
mediated. However there was no statistical difference in CTLA-4 mean fluorescence intensity 
given the number of cells analysed and further refinement of the transfection procedure may 
yield a higher number of shRNA
+ 
cells for analysis. To draw any inferences from this data it 
would be necessary confirm complete knock down of AP-2 by staining for CD-71 to ensure 
the clathrin pathway was fully inhibited. It can be noted that in a previous study assessing the 
completeness of AP-2 knock down by shRNA in HeLa cells the complex was still identified 
in clathrin-coated pits after shRNA transient transfection [62, 63]. In this study despite 
incomplete knock down internalisation of CD-71 was significantly reduced, but highlights the 
limitations of using interference RNA technologies. 
In HeLa cells analysis of shRNA
+ 
cells was hindered by the intensity of the RFP signal 
associated with transfected cells (Fig 3.13C). It is probable that the increased intensities of 
CTLA-4 staining observed in this experiment was a result of cross-emission of the different 
flurophores, therefore no affirmative conclusion could be drawn from this data. This 
phenomenon could be improved by 1) transfecting less shRNA 2) selecting an alternative 
shRNA construct that expressed less readily. 3) electronic compensation by staining with each 
fluorochrome individually to correct for spectral bleed-through.    
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In both shRNA knock down experiments considerable morphological changes were noted in 
transfected cells (Fig 3.12A). Cells appeared clustered together and were often 
multinucleated. As clathrin-mediated vesicular transport is shown to be important in the late 
phases of mitosis [63] it was considered that AP-2 knock down caused a significant disruption 
to cytokinesis. However changes were also observed in cells transfected with control 
constructs. Therefore it is more likely these changes were a negative consequence of the 
transfection procedure, again emphasising the importance of further optimisation in this 
system.  
In summary the endoytic behaviour of CTLA-4 was successfully compared to intracellular 
markers in a HeLa cell model and further repetition is required to draw more affirmative 
inferences on the acquired observations. Inhibition of clathrin-dependent endocytosis by 
shRNA knock down showed its potential for investigating the internalisation of CTLA-4, but 
at this stage could not support previous observations in our lab that the receptor can 
internalise via alternative endocytic pathways.  
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Abstract 
The phenotype of a T-lymphocyte can be defined by its expression of secretory cytokines. 
However, characterising the different T-cell lineages is challenging given the numerous 
subsets and significant overlap in cytokine profiles. Additionally the stability of a T-cell once 
fully differentiated is currently under review, with identifiable functional plasticity between 
different subsets. I investigated whether the recall cytokine response of CD4+ T-cells is 
influenced by the nature of the antigenic stimuli presented. PBMC were stimulated ex vivo 
with bacterial (SEB, PPD, Tetanus Toxoid), viral (EBV) and fungal antigens (yeast). IFNγ, 
TNFα, IL-17, IL-21 and IL-10 were stained intracellularly and expression analysed by flow 
cytometry. Results identified stimulus specific IFNγ, TNFα and IL-17 responses in the CD4+ 
CD45RO
+ 
memory population for all antigens tested; however no detectable IL-21 and IL-10 
secretion was established. There was variability in the ratio of IL-17
+ : IFNγ +  expression 
between different antigens indicating a potential Th17 or Th1 bias respectively. The ratio of 
TNFα+:IFNγ+ expressing cells was also variable, highlighting the potential significance of a 
TNFα+IFNγ- CD4+ population. Low number of responsive cells prevented comprehensive 
analysis of double positive cytokine secreting cells. However  the proportion of IFNγ+  cells 
also TNFα+ following PPD stimulation was notably but not significantly higher than the 
positive control (SEB), whereas the IL-17
+IFNγ+ proportions were similar. This study 
suggests but does not confirm that different antigenic stimuli cause an enrichment of 
differential T-cell subsets. Such findings are highly applicable to multiple disciplines 
involving cell-mediated immunity. 
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1.0 Introduction 
 
1.1 T-cell response to the local cytokine milieu drives differentiation and defines subset 
populations. 
T-lymphocytes have a central role in cell-mediated immunity and memory responses to 
previously encountered pathogens. Through selection processes in the thymus they are 
broadly divided into CD4 or CD8 subsets, dependent on their MHC-class restriction. Whereas 
CD8
+
 cells predominantly have a cytotoxic function and are involved in the elimination of 
virally infected or malignant cells, CD4
+ are termed ‘T helper cells’ (Th), and co-ordinated the 
type and severity of a recall response to a particular pathogen (reviewed in [64]). In order to 
acquire effector function naïve CD4
+
 cells both proliferate and differentiate following 
stimulation of the TCR. This is initiated by cognate interaction between the TCR and specific 
antigenic peptide bound to major histocompatibility complex (MHC) (expressed by antigen 
presenting cells) in conjunction with various co-stimulatory signals [65]. Cytokines are small 
immunomodulatory signalling molecules involved in cell-cell communication and directing a 
cells response to a particular environment. The recognition of these molecules by cytokine 
receptors expressed by T-cells initiates an intracellular signalling cascade that modulates the 
expression of particular target genes. This is achieved through changes in transcription factor 
activity, thus a cells cytokine profile is also often co-associated with specific transcriptional 
regulators  [66].  
Upon stimulation naïve T-cells secrete interleukin (IL)-2, which through a positive feedback 
loop induces the proliferation and the expansion of a cell responsive to a specific antigen. The 
expanded CD4+ population then differentiates into subpopulations dependent on the 
cytokines secreted by APC and other cells resident in the environment. The cytokine milieu 
itself is dependent on the nature of the pathogen through its interaction with pattern 
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recognition receptors, for example Toll-Like Receptors (TLR) [67]. In this way the CD4+ 
lineage is polarised towards the subset most effectively capable of dealing with the particular 
pathogenic agent. Historically there were two characterised subsets of CD4+ cells [68, 69]; 
Th1 are induced in response to IL-12 & IFNγ  and Th2 which predominantly differentiate in 
response to IL-4 and IL-2 (reviewed in [70]). IL-12 produces a Th1 phenotype through 
activity of the transcription factors STAT4 (signal transducer and activator of transcription-4) 
and IFNγ potentiates its own expression through Tbet induction by STAT1 [71]. In contrast 
IL-4 signalling is via STAT6 [72] and GATA3 [73] (trans-acting T-cell specific transcription 
factor-3) activity. Th1 cells are predominantly characterised by their secretion of interferon-γ 
(IFNγ) and a notable secretion of tumour necrosis factor-α (TNFα). Their function is 
associated with the eradication of intracellular pathogens such as viruses [74] and 
Mycobacterium species [75, 76]. Amongst many properties IFNγ is a potent inhibitor of viral 
replication and increases macrophage and NK cell activity whereas TNFα is an important 
systemic pro-inflammatory mediator. Th2 are defined by their expression of IL-4, IL-5 and IL-
13, and promote a more humoral response through stimulation of B-cell activation, 
proliferation and antibody class switching  [64] .  
In this Th1/Th2 model the polarisation towards a particular phenotype is potentiated through 
cytokines of one branch inhibiting the actions of another, for example, IL-4 induced GATA3 
expression transiently inhibits IFNγ production; thus blocking Th1 differentiation [77] . 
However, significant imbalance has been shown to be potentially pathogenic, with a Th2 
strong bias associated with increased susceptibility to both infection with intracellular 
pathogens and inflammatory allergic conditions. The latter is partially through  Th2 mediated 
increase in antibody class switching to IgE and eosinophil activity [78]. In children with 
allergic asthma the exposure to Th1 polarising antigens such as bacterial endotoxins has been 
shown to be protective, which demonstrates the importance of exposure to environmental 
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antigens in immune regulation. Although an attractive model in reality this Th1/Th2 theory is 
now known to be over-simplistic given the identification of multiple other subsets of Th cell, 
whose phenotype are also characterised by distinctive cytokine and transcription factor 
profiles. Examples of these include T regulatory cells (Treg) defined by expression of the 
transcription factor FOXP3 and CD25
(hi)
CTLA-4
(hi)
 surface markers (reviewed in [6]), and the 
recently identified pro-inflammatory Th17 subset [79, 80]. 
Th17 differentiate through a pathway independent of Th1 and Th2, with IL-6 [81] and TGFβ 
shown to be key determinants of the lineage [80, 82]. IL-23 is also associated, and as it is also 
secreted by Th17 may be additionally involved in maintaining the stability of the phenotype. 
This phenotype is predominantly characterised by the expression of the IL-17, IL-21 and IL-
23 through activation of the transcription factor RORC (RORγt in mice) [83]. Secretion of IL-
17 (predominantly IL17A and IL-17F) induces the secretion of other pro-inflammatory 
mediators and chemotactic agents which target numerous cell types. Th17 populations have 
shown to be responsive to extracellular pathogens and are shown to have particular 
importance in maintaining mucosal immunity [84, 85]. This subset are also notably 
responsive to fungal antigens, with clonal expansions of the populations been shown upon 
stimulation with Candida albicans [86] and other strains of yeast [87]. In a model of 
oropharyngeal candidiasis mice deficient in Th17 but not Th1
 
were shown to have an increased 
pathological susceptibility to opportunistic candida infection, thus demonstrating the subsets 
protective mucosal function [88, 89]. However, Th17 are also associated with inflammatory 
pathologies at these sites, and the neutrophil infiltration, mucosal inflammation and chronic 
airway remodelling observed in asthmatic patients has been partially attributed to Th17 activity 
[90, 91]. Additionally several autoimmune and inflammatory disorders were previously 
characterised through a dominant Th1 response, as blocking IL-12 ameliorates disease. 
However, IL-12 shares the p40 subunit with IL-23 and it was later found blocking IL-23 and 
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not IL-12 was required to abrogate disease in experimental models, thus linking Th17 to 
autoimmunity [92]. Knock out studies in mice have reported increased self-reactive Th17 
activity in models of arthritis [93], inflammatory bowel diseases and experimental 
autoimmune encephalomyelitis [92]. Additionally in humans and increased peripheral blood 
Th17 frequency has been associated with both rheumatoid arthritis [94] and Chron’s disease 
[95].  
1.2 Functional plasticity of CD4
+
 T-cell lineages 
Precisely identifying a cell phenotype is increasingly complex given the plethora of known 
cytokines and considerable overlap between the more recently identified subsets. For example 
both Th1and Th2 have been shown to secrete the anti-inflammatory cytokine IL-10 in addition 
to Treg.  In addition to this historically it was thought that differentiation of the CD4
+
 lineage 
was permanent, and there was no re-differentiation or switching of phenotypes between each 
subset. However the existence of subsets expressing an atypical cytokine profile of a 
combination of each subtype is increasingly being reported [80] (as shown in Figure 1.1). A 
population of cells expressing both IL-17 and IFNγ have recently been identified, and these 
cells express both Tbet and RORC transcription factors in mouse models. The question then 
arises, are these cells Th1 cells that have switched on IL-17 expression, or Th17 cells which 
have switched on IFNγ expression? In light of current understanding it appears these cells are 
of the Th17 lineage and also secrete IFNγ, and it has been shown that this IFNγ production by 
Th17 cells is associated with various pathologies, such as the inflammatory bowel disorder in 
Chron’s disease. The stability of each lineage has therefore come under particular scrutiny. It 
is yet to be demonstrated whether Th1 cells can be converted into Th2 or Th17 cells ex vivo, but 
evidence suggests that both Th2 or Th17 can be converted towards a Th1 phenotype under the 
IFNγ –rich polarising conditions [96] . In addition a population of IL-4/IL-17 dual secreting 
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cells have also been shown to be enriched in the lungs of chronic asthmatics, suggesting a role 
for Th2/Th17 hybrids in the inflammatory disorder [96].  Due to this apparent plasticity 
between T-cell lineages it is therefore extremely important to identify the initiator of such 
atypical gene expression, as the transcriptional regulators of such processes are yet to be 
elucidated. As a response to a specific pathogen can be polarised towards a specific T-cell 
lineage, this study aims to investigate whether recall responses to different pathogens can 
identify expansions of these novel subsets in an antigen-specific manner; thus demonstrating a 
pathogen-associated polarisation towards this differential gene expression. Therefore the 
frequency of these atypical dual cytokine secreting cells responsive to various bacterial, 
fungal and viral antigens will be investigated. Such research can potentially be applied to 
reverse phenotypes associated with disease, or drive differentiation of therapeutic benefit. The 
latter is analogous to processes within vaccine design, where agents such as novel adjuvants 
are being investigated to polarise a response to give the most effective long-lasting immunity 
to a particular pathogen. The significance of IL-17 responses in vaccine induced immunity 
have been investigated in animal models (reviewed in [97]). Adjuvants which provoke strong 
Th17 based immunity (such as cholera toxin) have been administered in conjunction with 
established vaccines to enhance the activity of this lineage to improve vaccine performance. 
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Figure 1.1 Differentiation and plasticity of CD4+ Th1, Th2 and Th17 cell lineages. Naïve T-cells 
proliferate to a pool of multi-potent progenitors through IL-2 expression. The cytokine milieu 
polarises differentiation towards a Th1, Th2 or Th17 phenotype; each defined by their own specific 
cytokine profile. Th17 can induce expression of Th1 and Th2 cytokines to form dual secreting 
populations expressing both classically-associated transcription factors. Th17 have been shown to 
revert to a fully Th1 phenotype secreting IFNγ alone. Some evidence suggests Th2 cells revert to a Th1 
phenotype with persistent IFNγ stimulation (image adapted from [98]). 
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1.3 Phenotypic analysis of infrequent cell populations 
As during a typical immune response only 0.001-0.0001% of T-cells are responsive to a 
specific antigen, the measuring of such small cell populations is challenging. Given that Th17 
cells represent such a small percentage of the T-cell population (and dual-secreting cells even 
less) this poses even further difficulties. ELISpot (enzyme-linked immunosorbent spot [99, 
100]) is a variation of the ELISA technique commonly used to characterize cells by the nature 
of their cytokine secretion (Figure 1.2). ELISpot is extremely sensitive, and can measure 
cytokine secretion at the level of individual cells. Cytokines secreted by cells stimulated ex 
vivo are captured extracellularly by specific antibodies coated to a plate. Binding of a second 
cytokine-specific reporter antibody (for example attached to a fluorochrome) produces a 
series of spots upon the plate that is proportional to the level of cytokine secretion of each 
responsive cell in the vicinity. However, the precise identification of the particular cells 
producing cytokine is limited due to the restrictions on multi-parameter staining for associated 
phenotypic markers. Additionally the number of cytokines that can be measured for particular 
cell is limited, making accurate phenotyping increasingly problematic. Therefore, staining for 
cytokine intracellularly (by blocking their secretion) and performing analysis by flow 
cytometry is an attractive alternative for phenotyping antigen-specific responses of T-cells 
[101]. Using this technique multiple parameters can be measured simultaneously, so a fuller 
cytokine profile of individual cells can be established. In addition, cells can be accurately 
phenotyped by staining for identifiable cell surface markers. In this investigation flow 
cytometry will be used to measure the antigen-specific cytokine responses of CD4
+
 T-cells in 
peripheral blood. This will be used to identify and characterize any antigen-induced expansion 
of cell populations expressing an atypical cytokine profile, for example cells secreting both 
IL-17 and IFNγ. 
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Fig 1.2 Cytokine detection by flow cytometry and ELISpot. A) Intracellular cytokine staining. 
Cells are stimulated and treated with a reagent to block exocytosis and trap expressed cytokines within 
the cell. They are then phenotyped by staining for associated surface markers. Fixing and 
permeabilisation allows antibody access to intracellular cytokines. These are then stained with using 
different fluorophores and analysed by flow cytometry. B) Extracellular cytokine staining. Cytokine-
specific antibody is coated on a polyvinylidene fluoride plate and non-specific binding blocked with 
serum. Cells and stimulant are incubated on the plate and cytokine secreted is captured by antibody in 
the immediate vicinity. Following washing the plate is incubated with a second antigen specific 
antibody conjugated to a reporter (fluorophore or biotin-streptavidin system). Plates are analysed with 
each spot representing cytokine secreted from an individual cell. 
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1.4 Aims 
 
Given the recently recognised plasticity between T-cell lineages [98] [102], it is important to 
further understanding of what environmental triggers influence each subsets gene expression. 
Additionally cells expressing an atypical cytokine profile are increasingly associated with 
autoimmune pathologies; thus demonstrating a functional significance of this expanded 
population in disease development. Such atypical cells are also candidate cellular biomarkers 
for particular diseases. For example, cells expressing both IFNγ and TNFα are shown to be 
elevated in active Mycobacterium tuberculosis infection compared to inactive disease, and 
can be used to distinguish between particular disease states [103]. This study aims to identify 
populations of CD4
+
 cells both IFNγ+TNFα+, and IFNγ+IL-17+ , and investigate whether they 
are expanded in recall response to various antigenic agents. The antigen-specific polarisation 
of a lineage towards such a dual-secreting phenotype will be demonstrated using flow 
cytometry, so multiple-phenotypic markers can be used to accurately define each cell line. As 
antigen-specific responses can polarise the lineage of a responsive cell on initial encounter, it 
may be anticipated that the phenotypes of cells responsive to a particular antigen may vary 
dependent upon the nature of the re-stimulation.  
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2.0 Materials and Methods 
2.1.1 Culture medium  
RPMI medium:      RPMI (Roswell Park Memorial Institute) 1640 [Sigma-Aldrich Irvine, 
UK] supplemented with 1% GPS (2mM l-glutamine, 100U/ml penicillin, 
100ug/ml streptomycin) [HyClone, Northumberland, UK] and 1% 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) [Sigma-
Aldrich]  
RPMI 10% HIFCS: RPMI 1640 medium supplemented with 10% Heat Inactivated Fetal 
Calf Serum (HIFCS) [Biosera, Ringmer, UK] 
RPMI 5% HS:       RPMI 1640 medium supplemented with 5% Heat Inactivated Human 
Serum (HIHS) [HS; HD Supplies, Aylesbury, UK] 
2.1.2 Antigens 
Abbreviation Antigen 
PMA/Ionomycin 
Phorbol 12-myristate 13-acetate (PMA) Ionomycin 
(IONO) [both Sigma-Aldrich]  
SEB 
Staphylococcus Enterotoxin B [Sigma-Aldrich Irvine, 
UK]   
PPD 
Purified Protein Derivative: Heat inactivated 
supernatant from cultures of virulent Mycobacterium 
tuberculosis [Statens Serum Institut, Copenhagen, 
Denmark] 
TetTox 
Toxoid from Clostridium tetani [EMD Chemicals 
Group, Darmstadt, Germany]. 
EBV 
Epstein Barr Virus: Antigenic peptides and lysates 
(kindly supplied by Prof Alan Rickinson group, 
Birmingham, UK).  
YEAST 
Heat-inactivated cells from overnight culture of 
Cryptococcus neoformans (capsular and Acapsular), and 
Crytococcus gattii (kindly supplied by Dr Robin May 
group, Birmingham, UK).  
 
Table 2.1 Antigens used to stimulate isolated peripheral blood mononuclear cells 
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Surface 
Markers Company Catalogue No. Dilution 
CD4 PE-
Cy7 
BD 
Biosciences 557852   1/20 
CD8 V500 
BD 
Biosciences 560774   1/20 
CD45RO 
PETR 
Beckman-
Coulter IM2712U   1/20 
Cytokine       
IFNγ 
eFluor450 eBioscience 48-7319-42   1/80 
TNFα 
PerCP-
Cy5.5 eBioscience 42-7349-42   1/40 
IL-17A 
FITC eBioscience  53-7179-42    1/20 
IL-21 PE eBioscience 12-7029-82   1/40 
IL-10 alexa 
fluor 647 eBioscience 51-7108-73   1/20 
 
Table 2.2 Antibodies used to characterise cells by flow cytometry. PE (Phycoerythrin), 
Cyanine 7 (Cy7), Phycoerythrin Texas Red (PETR), Peridinin-chlorophyll protein 
(PerCP), Cyanine 5.5 (Cy5.5), Fluorescein isothiocyanate (FITC), Allophycocyanin (APC). 
All antibodies were raised in mouse the alexa fluor 647 conjugate which was raised in rat.   
       
2.1.3 Additional Reagents 
Brefeldin A [Sigma,UK] 
Heparin Sodium [Leo Laboratories LTD, Bucks, UK] 
Ficoll-Paque Plus: [GE Healthcare Bioscience, Amersham, UK]  
PBS:                        Phosphate Buffered Saline (8g/l NaCl, 0.26/l KCl, 1.15g/l NA2HPO4,       
0.2g/ml KH2PO4); 1 PBS tablet added per 100ml distilled H20 [Oxoid, Basinstoke,UK]    
PBS 2%BSA:         PBS, 2% Bovine Serum Albumin (BSA) [Sigma-Aldrich] 
Cell Permeabilization Kit: [Caltag-Medsystems Limited, Bucks, UK] 
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Compensation beads: Anti-mouse and Anti-rat IgK/Negative control (FBS) compensation                               
 Particle set [BD Biosciences]  
 
2.2 Isolation of Peripheral Blood Mononuclear Cells (PBMC) 
Blood was extracted from the median cubital vein of healthy donors into a syringe. This was 
transferred into a 50ml falcon tube containing heparin sodium at 5IU/ml blood. Blood was 
diluted at a 1:1 ratio with RPMI and carefully layered over 7ml of Ficoll-Paque Plus into a 
25ml universal tube. Tubes were centrifuged at 400g with brake 0 for 30min. The individual 
layer was then extracted and transferred to a tube containing either RPMI 10% HIFCS or 
RPMI 5% HHS. Cells were washed twice at 300g before being counted using a 
haemocytometer. After a final wash cells were resuspended at 1x10
6
 cells per 50µl of 
supplemented medium. 
2.3 Antigenic Stimulation of Isolated PBMC  
2.3.1 Stimulation with PMA/Ionomycin  
1x10
6 
PBMC were added to wells of a 96-well plate in 50µl of RPMI 10% HIFCS. 
Unstimulated wells were used as a negative control and made up to 200µl with medium. For 
stimulated wells PMA and Ionomycin were added both at the concentration of 750ng/ml and 
the wells made up to 200µl. 2 µg/ml of Brefeldin A was added to both stimulated and 
unstimulated wells to prevent cytokine release. Cells were incubated at 37ºc and 5% CO2 for 
three hours. 
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2.3.2 Stimulation with T cell receptor specific antigens. 
PBMC required a more prolonged incubation for stimulation by antigens requiring T cell 
receptor engagement. Therefore 1x10
6 
PBMC were resuspended in 50µl of RPMI 5% HHS 
prevent any reactivity xenoantigens in HIFCS. Unstimulated wells were made up to 200µl 
with RPMI 5% HHS. The superantigen SEB was added to wells at 1µg/ml. The bacterial 
antigens PPD and TetTox were titrated between 0.01-50µl and 0.1-10 µg/ml respectively. For 
viral stimulation a mixture of nine known EBV antigenic peptides was used at 20ug/ml. In 
addition a lysate of whole virus isolated and enriched from EBV infected cells was used at 
10ug/ml [Virusys Corporation, US]. Yeast antigen was prepared by washing the cell cultures 
twice in PBS and counting using a haemocytometer. Between 1x10
3
 - 1x10
7 
cells were then 
added to the PBMC. A yeast lysate was also prepared by repeatedly freezing and thawing the 
cells every 30min between -80ºc and 37ºc. The lysate of 1x10
6 
cells was then added per well. 
All stimulated wells were made up to 200µl with RPMI 5% HHS and incubated for 16 hours 
at 37ºc and 5% CO2. 
2.4 Staining of cell surface markers and intracellular cytokines 
Cells were centrifuged in the 96-well plate for at 4ºC for 4min at 300g. The supernatant was 
flicked away and the cells were resuspended in 50µl of surface antibody in PBS 2%BSA. The 
plate left on ice in the dark for 15min. The cells were washed by addition of 150µl of PBS 
2%BSA and the centrifugation and supernatant removal repeated. Cells were then fixed for 
15min in the dark at room temperature by adding 50µl of Reagent A from the Catlag cell 
permeablisation kit. The wash step was repeated and cytokine antibodies added in 50µl of 
permeabilisation Reagent B. The plate was incubated at room temperature in the dark for 
15min. After a final washing the cells were resuspended in 100µl of PBS 2%BSA and stored 
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at -2ºC in preparation for flow cytometry. Prior to analysis cells were resuspended in a total of 
300µl. 
2.5 Flow cytometry and statistical analysis  
Cells were analysed for their surface marker and cytokine profiles on a Dako-Cyan flow 
cytometer using Summit v4.3 software. Compensation beads stained with each conjugated 
antibody individually were used to correct for spectral overlap. Positive cytokine signal was 
based above a threshold set using unstimulated cells. Due to the low cell numbers the absolute 
cell counts were taken and expressed as a percentage to two decimal places to improve 
accuracy. Statistical analysis was performed using GraphPad Prism 5. A non-parametric 
Wilcoxon matched pairs signed rank test was used to analyse differences in cytokine 
expression between the memory (CD45RO
+
) and naive (CD45RO
-
) lymphocyte populations. 
Friedman analysis of variance was used to compare the number of IL-17
+ to IFNγ+ and the 
number of TNFα+ to IFNγ+ secreting cells for each antigenic stimulation.   
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3.0 Results 
3.1 Optimisation of stimulation assay for detection of antigen specific responses 
It was important to optimise the simulation assay to maximise detection of the very small T 
cell populations responsive to a specific antigen. It was also essential to minimise the 
background or non-specific signals to discern true cytokine expression. Following PBMC 
isolation and analysis by flow cytometry the lymphocyte population was gated on to reduce 
contamination by monocytes and other cytokine producing cells (Fig 3.1A). The pulse width 
signal produced as cells pass through the flow cytometer was used to exclude cells stuck 
together as the cytokine profiles of these doublets are unrepresentative of individual cells. 
CD4 surface receptor was used to identify T helper subsets and CD45RO was used as a 
marker for memory antigen experienced cells (Fig 3.1B and Fig 3.1C). Any positive cytokine 
signal produced by naïve CD45RO
-
 lymphocytes was used as a measure of non-antigen 
specific background stimulation; this population was assumed to be quiescent and negative 
for the expression of IFNγ, IL-17, TNFα, IL-21 and IL-10. 
Initially 1x10
6 
PBMC were stimulated per condition, but this number proved insufficient to 
achieving responses distinguishable from background for such small T-cell populations. We 
therefore investigated the effect of increasing the number of cells stimulated per well of a 24-
well microtiter plate and analysed the IFNγ secreting population (Fig 3.2). Incubation with the 
superantigen SEB induced a population of IFNγ secreting CD4+CD45RO+ cells significantly 
more numerous than seen for unstimulated PBMC (Fig 3.2B-D). Increasing the number of 
stimulated PBMC did not significantly affect the percentage of IFNγ CD45RO+ cells, but did 
reduce the signal in the naïve populations (Fig 3.2E). The signal to background ratio was 
therefore more favourable at higher cell numbers and the protocol was adapted to allow for  
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the stimulation of more cells. Multiple wells were also stimulated and pooled prior to flow 
cytometry to further increase cell numbers.  
It was necessary to titrate the two chosen bacterial antigens (PPD and tetanus toxoid) to 
identify the optimal concentration to detect antigen specific responses. The pro-inflammatory 
cytokines IFNγ and IL-17 were used as a measure of successful stimulation. Tenfold dilutions 
of PPD induced IFNγ and IL-17 expression undistinguishable from background below the 
concentration of 1µg/ml (Fig 3.3D and E). However there was a dose dependent increase in 
cytokine production by the CD45RO
+
 population with greatest percentage expressing both 
cytokines at 10µg/ml (Fig 3.3C-E) which was the concentration used in subsequent 
experiments. Stimulation at 50µg/ml abrogated cytokine expression although it was not 
determined whether this was artifactual as the experiment was not repeated. 
The number of IFNγ and IL-17 responsive cells following tetanus toxoid stimulation was 
much less than seen with PPD stimulation. However ten-fold dilutions showed the optimal 
concentration to be 10µg/ml for IFNγ secretion with little influence in IL-17 response (Fig 
3.4). This concentration was considered adequate and no concentrations greater than this were 
tested due to the availability of the toxoid.   
3.2 Cytokine profiling of CD4+ T-helper lymphocytes following ex vivo stimulation 
A panel of monoclonal antibodies fluorescently labelled to different fluorochromes was then 
used to label IL-21, IL-10 and TNFα in addition to IFNγ and IL-17. This would identify 
variation in cells individual cytokine profile when stimulated with various antigens. When 
stimulated with the SEB the memory CD4
+
 cells produced significantly more of all five 
cytokines than the naïve CD4
+
 cells (Fig 3.5B and Fig 3.6A). This confirmed the limited 
ability of non-antigen experienced cells to secrete cytokine. As expected given the polyclonal 
nature of SEB activation the percentage of cytokine producing cells was significantly greater  
60 
 
 
61 
 
 
62 
 
than the other antigens tested and this was particularly notable for IFNγ expression. This was 
then used as a positive control in further experiments and compared with the antigen specific 
stimulations. Antigen induced IFNγ, IL-17 and TNFα responses significantly different from 
naïve CD4+  lymphocytes were detected in memory CD4+CD45RO+ populations following 
stimulation with PPD, tetanus toxoid and EBV lysates (Fig 3.6 B,C,D).  Of these antigens 
tetanus toxoid stimulated the least proportion of cells to secrete all three cytokines, whereas 
PPD induced cytokine secretion from the greatest proportion of memory cells (Fig 3.5C, 3.5E, 
3.6B, 3.6D). PPD and EBV lysate caused a similar very small percentage of memory cells to 
secrete IL-17 but PPD provoked a greater production of TNFα producers than EBV 
stimulation (Fig 3.5C-D,3.6B-C). Yeast lysate stimulation caused the largest increase in IFNγ 
expression (Fig 3.5F,3.6E), however this was in both naïve and memory s and there was 
repeatedly a smearing of low level IFNγ signal on the borderline of the negative vs positive 
gate (Fig 3.5F). However the IL-17 and TNFα response for memory cells was significantly 
different from naïve following yeast lysate stimulation.  
Excluding SEB there was no discernible difference in IL-21 and IL-10 secretion between 
naïve and memory CD4+ cells for all four antigens tested. For both cytokines the percentage 
of positive cells was extremely low in both populations.  
3.3 Polarisation of CD4+CD45RO+ cytokine responses by different antigenic stimuli 
It was then addressed whether different antigens polarised memory T-helpers cells to produce 
a different profile of cytokines upon stimulation. This was achieved by dividing the number 
of cells which expressed IL-17 or TNFα and dividing it by the number expressing IFNγ to 
give a cytokine
1
:cytokine
2
 ratio. For all antigens IFNγ was the cytokine produced by the 
largest number of cells. Compared to SEB it was found cells stimulated with PPD, EBV, 
Tetanus toxoid and yeast had a higher IL-17 : IFNγ ratio, with tetanus toxoid inducing a  
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statistically greater proportion of IL-17 expressing cells than SEB (Fig 3.7A, 3.7C). The low 
ratio seen with SEB indicates the response is dominated by IFNγ expression. There was also 
notable but not statistical differences in the IL-17 : IFNγ ratio between the different antigens. 
This may suggest polarisation toward Th17 driven IL-17 secretion and away from Th1 driven 
IFNγ secretion in recall responses dependent on the nature of the original stimuli (Fig 3.7A, 
3.7C).  
There was also a difference between antigens in the proportion of TNFα secreting cells 
compared to IFNγ secretors. Tetanus toxoid and PPD stimulation produced the highest 
proportion of TNFα positive cell and the ratio of TNFα: IFNγ expressing cells was ~1:2 and 
~1:2.5 for these antigens respectively. There was a statistical difference in ratio between these 
antigens and stimulation with yeast (characterised predominantly by IFNγ expression) which 
was the only significant difference between antigens. However EBV also did not seem to 
drive TNFα secretion from cells as much as PPD and tetanus toxoid and IFNγ producers were 
proportionally greater (Fig 3.7D). The EBV response was therefore characterised by an IL-17 
bias and limited TNFα production, whereas tetanus toxin and PPD appeared to have a more 
mixed repertoire of cytokine production less polarised towards IFNγ production.  
3.4 Dual cytokine secretion by stimulated CD4+CD45RO+ lymphocytes  
The proportion of stimulated IFNγ+ cells which co-expressed IL-17 or TNFα was calculated 
to identify differences in dual secretion under different stimulation conditions. As the 
population of double positive cells was so small SEB and PPD were the only antigens that 
simulated adequate cell numbers to analyse. The number of dual secretors was divided by the 
total number of cells expressing IFNγ. Under SEB stimulation ~10% of IFNγ expressing cells 
also expressed TNFα whereas ~30% secreted both cytokines when stimulated with PPD (Fig 
3.7E), however this finding was not statistically significant at p<0.05. The number of IFNγ+ 
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cells co-expressing IL-17 was comparable for SEB and PPD stimulations and represent a very 
small proportion of the IFNγ+ (~3%). This very small population was the most difficult to 
discern from background staining. 
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4.0 Discussion 
ELISpot is a sensitive method for analysing cytokine secretion at the level of individual cells 
and is commonly used to measure antigen-specific recall responses due to the minimal 
number of responsive lymphocytes. Therefore for such purposes it is reported that ELISpot 
techniques are favourable over flow cytometry analysis for low level detection [104]. 
However the latter is advantageous as each individual cytokine secreting cell can be precisely 
identified. Additionally more comprehensive cytokine profiling is permitted as multiple 
parameters per cell can be measured simultaneously, thus such work is represented in current 
published literature [105]. By optimising a flow cytometry protocol it was possible to measure 
differential expression of three out of five tested cytokines in response to ex vivo re-
stimulation with four antigens. However the study has also highlighted the difficulties of 
measuring antigen specific responses, and suggested the method may not be appropriate for 
all antigenic stimuli. On evaluating findings the biological variability influencing T-cell 
responses was potentially a limitation given the number of experimental repeats, with the 
following being the most notable: 1) genetic immune variability 2) vaccination history 3) age 
4) previous infection (symptomatic or asymptomatic) 5) geographical exposure to 
environmental antigens. For example following stimulation with PPD 0.55% of one 
individuals CD4
+ 
cells showed an antigen specific IFNγ response, whereas only 0.09% 
responded in another participant. This demonstrates significant biological variability given the 
small cell numbers measured. 
The CD4
+
 and CD8
+
 T lymphocyte populations were identified and analysis was focused on 
the CD4
+
 T helper subset, as these are central in orchestrating the nature of memory responses 
on subsequent antigenic challenges. A Th1 phenotype was characterised by expression of the 
classically associated cytokine IFNγ and a Th17 phenotype was characterised by IL-17 
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expression. The expression of transcription factors associated to a lineage in conjunction with 
cytokine profile can also add evidence to a lymphocytes true subset. In preliminary flow 
experiments it was found that nearly all IFNγ+ cells co-expressed the archetypal Th1 
transcription factor Tbet, IL-5
+
 cells co-expressed the classic Th2 transcription factor GATA3 
(<97% when compared to matched isotype controls) and IL-17
+
 cells co-expressed the Th17 
associated transcription factor RORC. Despite this such categorisation is not definitive and is 
generalised given the complex overlap in cytokine profiles with other T-cell lineages, for 
example the multiple T regulatory subsets.  However in addition to IFNγ and IL-17 the 
expression of proinflammatory cytokines TNFα, IL-21 and anti-inflammatory IL-10 was also 
measured for a more complete perspective on CD4+ responses. 
The superantigen SEB was used as a positive control for successful stimulation and induced a 
significantly greater population of memory CD4
+
 cells to secrete all five cytokines when 
compared to naive. Naïve T-cell secrete IL-2 and not inflammatory cytokines on TCR 
peptide-HLA ligation as the necessary genes are not expressed without prior antigenic 
exposure.  SEB cross links the Vβ chain of the T cell receptor to HLA molecules on antigen 
presenting cells resulting in polyclonal activation of both CD4
+
 and CD8
+
 T-cell [106]. This 
explains why the number of responsive T-cell is significantly greater than stimulation with 
more specific antigenic agents. However not all T-cell are SEB responsive as the antigen only 
binds specific variants of the Vβ chain with Vβ8 being the most notable [107]. An 
individual’s T-cell response to SEB will therefore vary depending on their specific vβ 
repertoire. In keeping with the literature it was found SEB induced the most CD4
+
 T-cell to 
produce IFNγ in preference to other cytokines, suggesting a dominant Th1 response. There 
was also significant amounts of TNFα production which the systemic inflammation caused by 
the enterotoxin is physiologically partially attributed to [108]. SEB also stimulated a 
population of memory CD4 cells to produce IL-17 suggesting the antigen activates the small 
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population of Th17 memory cells. The ratio of IL-17
+
: IFNγ+ was low as expected given the 
Th17 frequency (under the assumption that the frequency of SEB binding Vβ chains is equal 
within both Th1 and Th17 subsets).  
IL-21 secretion has recently been associated with Th17 differentiation and effector function 
[109-111] . However SEB stimulation was the only circumstance in which detectable 
differences between naïve and memory populations for IL-21 could be distinguished (no 
correlation between IL-21 and IL-17 secretion was noted).  With specific antigen stimulation 
this may have been because A) Given the minimal cell numbers and only <0.05% of memory 
CD4
+
 responding to IL-21 secretion this could not be distinguished from background. B) The 
quality of staining with the IL-21 antibody was not sufficient to distinguish between truly 
positive cells and non-specific binding. This scenario was also true for analysis of IL-10 
secretion, and both cytokines were therefore excluded from further analysis of the four 
antigens. However the positive control did produce an IL-10 response which may be 
attributed the intensive stimulation by the superantigen as IL-10 is shown to be upregulated in 
response to excessive or chronic stimulation [112].  
The CD4
+ 
cytokine responses to the two bacterial stimuli tested were different in both degree 
and nature. PPD and tetanus toxoid were chosen to increase the probability of prior exposure 
given the routine childhood vaccination program in the UK. The fact some individuals in the 
cohort may not have been exposed to vaccine (or environment antigen in the case of PPD) has 
to be considered as no vaccination history was taken, which may make the average results 
under-representative. 
PPD induced more cells to secrete IFNγ and TNFα than tetanus toxin, but the difference 
between IL-17 secretion was not statistically significant. The reason re-challenge with PPD 
may produce a stronger response than tetanus toxoid is immunisation against mycobacterium 
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tuberculosis is a live attenuated vaccine which evidence shows provides long lasting 
immunity. This may be through increased initial expansion of CD4
+
 populations or prolonged 
antigenic stimulation by persistence of the attenuated strain [113]. Toxoid vaccinations do not 
provide lasting immunity and require ten yearly boosters during adulthood. There is evidence 
adult immunity to tetanus declines with age due to lack of uptake of necessary booster 
vaccines [114], and this may contribute to the average toxoid responsive being marginal even 
at the optimal concentration tested. Despite this there was a small notable difference in the 
ratio of IL17
+:IFNγ+ producing cells between the two antigens. The ratio on tetanus toxoid 
stimulation was elevated, perhaps suggesting either there is a greater clonal expansion of Th17 
on vaccination, or those Th17 cells persist longer than the Th1 population. TNFα
+
: IFNγ+  
ratios were also varied yet it is difficult to speculate on both the phenotype of this population 
of cells which secretes TNFα without IFNγ+ and the significance of the differential ratios 
given the limited cytokines analysed. However the significance of this TNFα+IFNγ- 
population has recently been highlighted in context of M. Tuberculosis infection. A. Harari et 
al a significantly elevated population of TNFα+IFNγ- cells in active compared to latent M. 
Tuberculosis infection. The sensitivity of this distinction was substantial enough that the 
TNFα+IFNγ- population is candidate cellular biomarker for active tuberculosis. 
 
To test polarisation of cytokine profiles in response to fungal antigens we used two strains of 
Cryptococcus found in soil (the opportunistic Cryptococcus Neoformans and Cryptococcus 
Gatii which infects immunocompetent hosts). It is reported cryptococcal strains are found 
world-wide [115], however significant exposure of the cohort could not be presumed given 
current epidemiological evidence. It is also reported the major epitope is a 
glucuronoxylomannan [116], a component of the polysaccharide capsule surrounding the 
organism. However conflicting reports suggest major epitopes are in fact hidden beneath the 
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capsule masking them from immune surveillance and making the coat a virulence factor in 
itself [117, 118]. Yet despite using an acapsular strain of the species stimulation with whole 
organisms proved ineffective in a preliminary experiment, so a mixed lysate was created to 
increase antigen availability. Lysate stimulation produced considerable low level IFNγ signal 
in both the naïve and memory CD4
+ 
pools. This may be non-specific stimulation by the lysate 
or non-specific binding of the staining antibodies to components of the yeast cells in the prep. 
The latter is less likely given the same background was not seen with the IL-17 or TNFα 
antibodies and a significant number of memory T-cell were stimulated when compared to 
naïve. It is therefore possible there is some specific IFNγ signal masked by the considerable 
background. Given this IFNγ signal unreliability it is not possible to draw any inferences from 
the ratios with other cytokines as the value would be a considerable under representation. 
However it can be noted that the IL-17 signal was strong when compared to other antigens 
and may support evidence in the literature that Th17 cells have a key role in mucosal immunity 
against fungal infections . It is also demonstrated that IL-17 and the associated IL-23 have a 
role in preventing opportunistic infections. In mice challenged with Cryptococcus 
Neoformans deficiency in both Th17 and Th1 is significantly more lethal than Th1 deficiency 
alone. In further support impaired Th17 derived immunity has been associated with pathogenic 
candidiasis through infection with Candida Albicans, another fungal opportunistic infection.  
EBV is largely endemic with <80% of individuals latently infected. Much work has focused 
around the CD8
+
 cytotoxic response of the virus but little is known about the CD4
+
 responses, 
particularly in latency. Initially we used a combination of nine EBV-derived peptides for a 
specific HLA type and stimulated PBMC from a HLA matched donor. However this achieved 
little response and had the added constraint of HLA haplotyping every participant in the 
cohort. A whole EBV lysate was then tested and a significant number of responsive EBV 
specific memory CD4
+
 cells were identified, with ~0.1% responding with IFNγ expression. 
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This may be expected given the potent antiviral properties of the molecule and its importance 
in control of intracellular pathogens. This is in keeping with evidence that CD4
+ 
response to 
Epstein-Barr Nuclear Antigen 1 (the major latency antigen) is strongly polarised towards a 
Th1 phenotype. However there are conflicting reports all dependent on the nature of 
stimulatory peptides examined. In the case of Herpes Simplex Virus; another virus with a 
latent and lytic cycle, IFNγ secretion around infected neuronal ganglion is essential for 
maintaining the virus in its latent phase and preventing reactivation. This is not restricted to 
CD8+ cytotoxic cells, and CD4+ cells have been shown to have a particularly important role 
in the latency phase when the density of viral antigens is less dense. 
I identified very few TNFα+ CD4+ memory cells despite an apparent EBV specific IFNγ 
response (particularly compared to PPD simulation). It may be speculated the cytokine profile 
of EBV CD4
+
 T-cell is deliberately skewed away from TNFα expression to prevent 
pathological damage given the persistence of the virus. IL-17 was also produce by a small but 
notable number of cells, which supports the suggestion IL-17 has a role in maintaining 
persistent viruses in the latency phase. 
 
 In this study it is important to note that changes in cytokine profiling cannot be attributed to 
differential TCR signalling as both antigen presenting cells and T-cell have an array of other 
pathogen pattern recognition receptors, for example Toll-Like Receptors. These substantially 
contribute to lineage polarisation of naïve T-cell and potentially influence memory T-cell 
phenotype upon re-stimulation. The contribution of the TCR could be equated by functionally 
blocking HLA molecules on APC to prevent peptide presentation on stimulation. The 
cytokine contribution from the non-TCR specific portion could then be subtracted. This 
would be particularly useful when using lysates and vaccine preparations which may contain 
contaminants or adjuvants. Alternatively tetrameric MHC-peptide complexes could be used 
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for stimulation purposes but this requires HLA haplotyping and sequence information of 
stimulatory peptide fragments.   
The contribution antigenic milieu receptor combination is important when considering when 
considering the plasticity of particular lineage and what drives a subset to express an atypical 
cytokine. SEB and PPD were the only antigens stimulating adequate cell numbers to analyse 
the co-secretion of TNFα or IL-17 with IFNγ. Only around 10% of IFNγ producing cells also 
produced TNFα following SEB secretion compared to 30% with PPD. This possibly 
represents a population of Th1 co-secretors and supports the association of TNFα with a Th1 
phenotype for the purpose of activating macrophages and other inflammatory cells. However 
it can be as easily speculated these are an unidentified subset of TNFα secretors that have 
switch on IFNγ expression. Evidence gathered supported the existence of an IL-17/IFNγ co-
secreting population and their numeracy suggested this combination of cytokines is extremely 
rare. However not enough antigens were tested to speculate whether different antigenic 
stimuli influenced either population of co-secretors examined.   
 
In summary this study has demonstrated the feasibility that different antigenic stimuli can 
cause differential cytokine profiles in CD4+ cells. Given these changes can be detected in 
healthy individuals without any clonal expansion associated with in vivo re-challenge or 
reactivation this is useful for comparison of non-pathological versus pathological 
presentation. For example, in the case of EBV infection it is possible to compare the T-cell 
cytokine profiles of seropositive individuals who don’t present with infectious mononucleosis 
to those who develop the disease . Additionally longitudinal of IM patients during primary 
infection, subsequent symptomatic presentation and when the EBV virus is in a non-reactive 
state could identify any changes in CD4 T-cell phenotype. This is important given the 
historical black and white Th1 Vs. Th2 classification is no longer considered applicable given 
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the discover of numerous sublineages and overlap in cytokine profile. The approach is also 
applicable for demonstrating the plasticity and stability of a specific sublineage which itself 
adds an additional layer of complexity phenotypic analysis. Such approaches are also 
applicable to vaccine design where it is desirable to polarise a T-cell response to provide the 
most effective immunity against a pathogen of interest.  
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